Octaviant Financial, Inc. (OFX) provides innovative financing and reimbursement strategies for high-cost therapies, including breakthrough gene and cell therapies. We have designed a suite of highly proprietary products rooted in the fields of fintech, insurance, and value-based medicine to address concerns over the affordability of high-cost therapies, their potential lack of durability, and patient mobility once they have received treatment. Our ideas are straightforward and we have brought together a team of talented people whose mission it is to make healthcare possible for as many people as imaginable. Our products are designed to make transformative high-cost therapies more affordable and to mitigate the risk to a payer if a therapy fails. We combine structured financial solutions with a mix of specialized insurance instruments to offset risk, addressing the high cost and uncertain durability of these drugs. Best of all, a feature of our concept is the eventual portability of our products, enabled by their proprietary structure. This means as patients move from one insurer to another, the cost of prior care and obligations will be able to travel with the beneficiary. Whether you are a drug manufacturer seeking to reduce financial barriers for your payers, or a payer facing a high-cost charge for a breakthrough therapy, we have products tailored for your situation.